New filings for Eisai's Fycompa despite reimbursement woes
This article was originally published in Scrip
Executive Summary
Eisai has filed its anti-epileptic Fycompa (perampanel) for use as an adjunctive therapy in people with uncontrolled primary generalized tonic-clonic seizures (PGTC), an additional indication, in the US and EU.